Similarly, in melanoma, treatment with MAPK inhibitors elevates FAK activation in human BRAF V600E melanoma cells,46 suggesting that FAK activation represents an intrinsic resistance mechanism triggered by MAPK inhibition. The gene discussed is PTK2; the disease is melanoma.